Daniel J. Hicklin
Founder, CEO, President & DirectorDr. Daniel J. Hicklin, also known as Dan, Ph.D., Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019 and serves on its Board of Directors since October 2017. He served as Secretary of Werewolf Therapeutics, Inc. and served as its Treasurer. He serves as President and Director at Trieza Therapeutics, Inc. He also serves as the Advisor at MPM Asset Management, L.L.C. Previously he was the Executive Partner and prior to that, as a Managing Director at the firm. He joined MPM in March 2014, subsequent to his role as President, Chief Scientific Officer and Member of the Board of CoStim Pharmaceuticals from August 2013 to February 2014. He served as Vice President of Immunology at Imclone Systems LLC at ImClone Systems LLC. From 2007 to 2013, he held several positions at Merck Research Laboratories, most recently leading Biologics Strategy for Oncology and the Immuno-modulation Discovery team. In these roles, he oversaw many oncology discovery and development projects including the portfolio of projects that Merck had developed in the exploding immuno-oncology area. During his career, he has complemented his scientific and leadership accomplishments with extensive past work across all phases of small molecule and biologics drug development. He founded Potenza Therapeutics (acquired by Astellas Pharma) where he was President and CEO from April 2014 to December 2018 and was on the Board of Directors of Harpoon Therapeutics and the scientific advisory Board of Oncorus. He also served as an Executive Partner at MPM Capital from 2014 to December 2019 and an advisor from January 2020 to December 2022. Prior to joining Schering-Plough, he held several positions of increasing responsibility at ImClone Systems from 1987 to 2007, including serving as Vice President of Experimental Therapeutics. He has been a Director of Maverick Therapeutics, Inc since 2016. He serves as a Director of Tizona Therapeutics, Inc. His team at ImClone supported the development and FDA approval of the cancer treatment ERBITUX (Cetuximab) and built a diversified portfolio of antibody therapeutics including ramucirumab, cixutumumab, necitumumab and other agents that were acquired by Eli Lilly. From 1996 to 1999, he was an Assistant Professor at New York Medical College. He also serves on the Industry Advisory Board for The Mark Foundation for Cancer Research. He holds an M.S. and Ph.D. in Microbiology and Immunology from New York Medical College and a B.S. from the University of Iowa.
公司職務
- 公司名稱Werewolf Therapeutics, Inc.股票代碼HOWL職務Founder, CEO, President & Director
